CD45 antibody | YKIX716.13
Mouse anti Canine CD45 antibody, clone YKIX716.13 (MCA1042GA) used as part of a panel of antibodies to demonstrate the phenotype of canine mesenchymal stem cells by flow cytometry together with mesenchymal markers CD9, CD44, CD90 and CD105. Negative results for lineage cell markers CD34, CD45 and STRO-1 are shown.
Image caption:
b. Representative histograms demonstrating positive and negative staining of marrow cMSCs from a single donor
From: Bearden RN, Huggins SS, Cummings KJ, Smith R, Gregory CA, Saunders WB.
In-vitro characterization of canine multipotent stromal cells isolated from synovium, bone marrow, and adipose tissue: a donor-matched comparative study.
Stem Cell Res Ther. 2017 Oct 3;8(1):218.
Flow cytometric analyses of optimized platelet samples after density barrier centrifugation. (A) Log forward and side scatter chart of platelet population (gated) with minimal contaminating cells. (B) Fluorescence chart of CD45 (FL2) and CD61 (FL1) antibody-labeled samples. Average CD61+: 99.47 ± 0.21% (n=3). Average CD45+: 0.19 ± 0.04% (n=3). (C) LeucoCOUNT chart for sample showing residual leukocytes (left gate) and LeucoCOUNT beads (right gate).
From: Trichler SA, Bulla SC, Thomason J, Lunsford KV, Bulla C.
Ultra-pure platelet isolation from canine whole blood.
BMC Vet Res. 2013 Jul 17;9:144.
Mouse anti Canine CD45 antibody, clone YKIX716.13 (MCA1042GA) used for the evaluation of CD45 expression on canine bone marrow-derived mesenchymal stem cells by flow cytometry.
Image caption:
The phenotype of cultured bone marrow-derived mesenchymal stem cells (BM-MSCs) from each dog was confirmed before autologous injection.
Expression of CD29, CD34, CD44, CD45, and CD90 by cultured cells was evaluated by flow cytometric analysis using anti-CD29, anti-CD34, anti-CD44, anti-CD45, and anti-CD90 antibodies, after selection of the cell population of interest. Control isotype antibody is plotted in red in each histogram plot. Cultured cells were confirmed as BM-MSCs by their appearance in culture and by the CD29+CD44+CD90+CD34-CD45- phenotype.
From: Muir P, Hans EC, Racette M, Volstad N, Sample SJ, Heaton C, et al. (2016)
Autologous Bone Marrow-Derived Mesenchymal Stem Cells Modulate Molecular Markers of Inflammation in Dogs with Cruciate Ligament Rupture.
PLoS ONE 11(8): e0159095.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Rat anti Dog CD45:Alexa Fluor® 488
Rat anti Dog CD45:Alexa Fluor® 647
Rat anti Dog CD45:APC
Rat anti Dog CD45:Biotin
Rat anti Dog CD45:FITC
Rat anti Dog CD45
Rat anti Dog CD45:RPE
- Product Type
- Monoclonal Antibody
- Clone
- YKIX716.13
- Isotype
- IgG2b
Rat anti Dog CD45 antibody, clone YKIX716.13 recognizes canine CD45 also known as leukocyte common antigen lustered as Canine CD45 in the First Canine Leukocyte Antigen Workshop (CLAW). Clone YKIX 716.13: immunoprecipitates an antigen of ~180/200 kDa from Con-A blasts (Cobbold et al. 1994). CD45 is expressed on all leukocytes in canine peripheral blood. Rat anti Dog CD45 antibody, clone YKIX716.13 reacts with CD45 on all outbred mongrels and beagles tested and may be against CD45RB isoform.
Product Details
- Target Species
- Dog
- Product Form
- Purified IgG conjugated to Alexa Fluor® 488 - liquid
- Product Form
- Purified IgG conjugated to Alexa Fluor® 647 - liquid
- Product Form
- Purified IgG conjugated to Allophycocyanin (APC) - lyophilised
- Product Form
- Purified IgG conjugated to Biotin - liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Reconstitution
- Reconstitute with 1ml distilled water
- Reconstitution
- Reconstitute with 1ml distilled water
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Carrier Free
- Yes
- Immunogen
- Canine thymocytes.
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised DA rats were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 12 months from date of reconstitution.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 12 months from date of reconstitution.
More Information
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Regulatory
- For research purposes only
Applications of CD45 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | Neat | 1/5 | |
| Flow Cytometry | Neat | 1/5 | |
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | 1/5 | |
| Flow Cytometry | 1/50 | 1/100 | |
| Immunoprecipitation | |||
| Flow Cytometry | Neat | 1/10 |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) | STAR131A | 1 ml | C E P WB | ||
| Goat anti Rat IgG:Biotin (Mouse Adsorbed) | STAR131B | 0.5 mg | C E IF P WB | ||
| Rabbit F(ab')2 anti Rat IgG:Dylight®800 | STAR16D800GA | 0.1 mg | F IF WB | ||
| Rabbit F(ab')2 anti Rat IgG:FITC | STAR17B | 1 mg | F | ||
| Rabbit F(ab')2 anti Rat IgG:HRP | STAR21B | 1 mg | C E P RE | ||
| Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) | STAR69 | 0.5 ml | F | ||
| Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) | STAR71D800GA | 0.1 mg | F IF WB | ||
| Goat anti Rat IgG:HRP (Mouse Adsorbed) | STAR72 | 0.5 mg | C E P | ||
| Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) | STAR73 | 0.5 ml | F |
Negative Isotype Controls Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Rat IgG2b Negative Control:Alexa Fluor® 647 | MCA6006A647 | 100 Tests/1ml | F | ||
| Rat IgG2b Negative Control:APC | MCA6006APC | 100 Tests | F | ||
| Rat IgG2b Negative Control:Biotin | MCA6006B | 0.1 mg | F | ||
| Rat IgG2b Negative Control:FITC | MCA6006F | 0.1 mg | F | ||
| Rat IgG2b Negative Control | MCA6006GA | 0.1 mg | F | ||
| Rat IgG2b Negative Control:RPE | MCA6006PE | 100 Tests | F |
Product Specific References
References for CD45 antibody
-
Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
Tissue Antigens. 43 (3): 137-54. -
Reis, A.B. et al (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi.
Clin Exp Immunol.146: 303-11. -
Stein, V.M. et al. (2008) Immunophenotypical characterization of monocytes in canine distemper virus infection.
Vet Microbiol. 131:237-46. -
Sanchez, M.A. et al. (2004) Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with Leishmania chagasi.
Am J Trop Med Hyg. 70: 618-24. -
Modiano,J.F. and Helfand,S.C. (2011) Early detection of hemangiosarcoma and angiosarcoma
Patent Application No.11/662529 -
Tominaga, M. et al. (2010) Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma.
J Vet Diagn Invest. 22: 438-41. -
Zentek, J. et al. (2002) Morphology and immunopathology of the small and large intestine in dogs with nonspecific dietary sensitivity.
J Nutr. 132: 1652S-4S. -
Hunter, M.J. et al. (2011) Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression.
Mol Ther. 19: 113-21. -
Comazzi, S. et al. (2006) Flow cytometric patterns in blood from dogs with non-neoplastic and neoplastic hematologic diseases using double labeling for CD18 and CD45.
Vet Clin Pathol. 35: 47-54. -
Giantin, M. et al. (2013) Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: might c-KIT represent a therapeutic target?
Vet Immunol Immunopathol. 152: 325-32. -
Trichler, S.A. et al. (2013) Ultra-pure platelet isolation from canine whole blood.
BMC Vet Res. 9: 144. -
Aresu, L. et al. (2014) VEGF and MMP-9: biomarkers for canine lymphoma.
Vet Comp Oncol. 12: 29-36. -
Salinas Tejedor, L. et al. (2015) Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system.
Brain Behav Immun. pii: S0889-1591(15)00233-0. -
Muir, P. et al. (2016) Autologous Bone Marrow-Derived Mesenchymal Stem Cells Modulate Molecular Markers of Inflammation in Dogs with Cruciate Ligament Rupture.
PLoS One. 11 (8): e0159095. -
Poggi, A. et al. (2017) Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma.
Vet Comp Oncol. 15 (2): 431-440. -
Zeira, O. et al. (2015) Adult autologous mesenchymal stem cells for the treatment of suspected non-infectious inflammatory diseases of the canine central nervous system: safety, feasibility and preliminary clinical findings.
J Neuroinflammation. 12: 181. -
Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
Vet Immunol Immunopathol. 159 (1-2): 91-6. -
Michael, H.T. et al. (2013) Isolation and characterization of canine natural killer cells.
Vet Immunol Immunopathol. 155 (3): 211-7. -
Nishimura, T. et al. (2017) Feeder-independent canine induced pluripotent stem cells maintained under serum-free conditions.
Mol Reprod Dev. 84 (4): 329-339. -
Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
Immunobiology. 221 (1): 12-22. -
Bearden, R.N. et al. (2017) In-vitro characterization of canine multipotent stromal cells isolated from synovium, bone marrow, and adipose tissue: a donor-matched comparative study.
Stem Cell Res Ther. 8 (1): 218. -
Lee, S.H. et al. (2016) Impact of local injection of brain-derived neurotrophic factor-expressing mesenchymal stromal cells (MSCs) combined with intravenous MSC delivery in a canine model of chronic spinal cord injury.
Cytotherapy. Oct 28 [Epub ahead of print].
